TASE:BONS
Oramed Pharm - is a clinical stage biopharmaceutical company.
2022/3 Planned launch of MesenCure multinational phase III clinical trial; and phase II/III clinical trial in the US evaluating the safety and efficacy of BonoFillTM injectable live bone graft for bone regeneration.
2022/3 Planned launch of MesenCure multinational phase III clinical trial; and phase II/III clinical trial in the US evaluating the safety and efficacy of BonoFillTM injectable live bone graft for bone regeneration.
註釋
It's Bonus Biogroup, of course! Wrong company name in description was mistakenly copy-pasted (!)
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。